CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Communiqués Charles River Laboratories International, Inc.

Actions

CRL

US1598641074

Marché Fermé - Nyse Autres places de cotation 22:00:02 31/05/2024			Varia. 5j.	Varia. 1 janv.
208,4 ^USD	-0,61 %		-4,04 %	-11,83 %

30/05	Charles River Laboratories International, Inc. lance un programme de transfert de technologie des vecteurs viraux pour protéger le développement de la thérapie génique	CI
15/05	Transcript : Charles River Laboratories International, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development	30/05	BU
Charles River: Q1 Earnings Snapshot	09/05	AQ
Charles River Laboratories Announces First-Quarter 2024 Results	09/05	BU
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP	02/05	BU
Charles River Laboratories International : Proxy Supplement Filed April 24, 2024	24/04	PU
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally	22/04	BU
Charles River Laboratories International : 2023 Corporate Citizenship Report	22/04	PU
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing	16/04	BU
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call	15/04	AQ
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call	12/04	BU
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology	11/04	BU
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics	09/04	BU
Charles River to Perform Plasmid Production for Ship of Theseus	04/04	BU
Charles River to Perform Plasmid Production for Ship of Theseus	04/04	BU
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024	01/04	BU
Charles River Laboratories Publishes 2023 Corporate Citizenship Report	27/03	BU
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine	21/03	BU
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration	14/03	BU
Charles River Laboratories to Present at Barclays Global Healthcare Conference	12/03	BU
Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use	29/02	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Charles River Laboratories International, Inc.

Actions

CRL

US1598641074

Communiqués

Filtres